Harry Yoon is Associate Professor of Oncology at Mayo Clinic. OpenAlex indexes 246 publications with 8,337 citations (h-index 32); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Harry Yoon, M.D., is Associate Professor of Oncology at Mayo Clinic. The public record shows 246 publications with 8,337 citations (h-index 32), centered on Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 12 companies, 1 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Gastric Cancer Management and Outcomes
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 57.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
Sponsor: CARsgen Therapeutics Co., Ltd.
- Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Sponsor: Hoosier Cancer Research Network
Industry payments
Updated 18 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.3%CD38-directed Cytolytic Antibody31.5%Daratumumab100%Part B, office-administered≥22 patientsPD-1 inhibitor30.8%Pembrolizumab100%Part B, office-administered≥16 patients+ 2 more classes in this area
Metabolism & gastrointestinal
24.4%Other antiemetics18.9%Fosaprepitant100%Part B, office-administered≥15 patientsSerotonin-3 Receptor Antagonist5.3%Ondansetron hydrochloride51%Palonosetron hcl43%Ondansetron Hcl5%Part D + Part B≥37 patients+ 2 more classes in this area
Sensory organs
4.4%Corticosteroid4.4%Dexamethasone sodium phosphate94%Dexamethasone6%Part D + Part B≥45 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2021–2026 per NIH RePORTER. The latest:
- Overcoming Immunotherapy Resistance in Patients with Metastatic Gastric/Esophageal Adenocarcinoma
Mayo Clinic Rochester
FY2026$748,291R01CA248147 - Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
Mayo Clinic Rochester
FY2025$627,404R01CA248147 - Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
Mayo Clinic Rochester
FY2024$591,765R01CA248147
Congress activity
Updated 18 Oct 2026
55 congress contributions (2009–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Impact of sarcopenia on short- and long-term outcomes after multimodal therapy for esophageal cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma.
JCO precision oncology
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyArticle1,684 citations2022
- 03
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/harry-yoon-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dmr.amegroups.org ↗
- Co-chair for Research
Gastroesophageal Cancer Disease Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dmr.amegroups.org ↗ - Member
Guidelines Panel for Unknown Primary
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dmr.amegroups.org ↗ - Member
Gastroesophageal Cancer Task Force
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dmr.amegroups.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
Esophageal/Gastric Working Group, NCI Alliance cooperative group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dmr.amegroups.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH